Des(1-3)IGF-1

Des(1-3)IGF-1
Clinical data
Routes of; administration	Intravenous administration
ATC code	None;
Identifiers
CAS Number	112603-35-7 ;
ChemSpider	none;
UNII	AG0WVP88OA;
Chemical and physical data
Formula	C319H501N91O96S7
Molar mass	7371.48 g·mol−1

des(1-3)IGF-1 is a naturally occurring, endogenous protein, as well as drug, and truncated analogue of insulin-like growth factor 1 (IGF-1).^[1]^[2]^[3]^[4] des(1-3)IGF-1 lacks the first three amino acids at the N-terminus of IGF-1 (for a total of 67 amino acids, relative to the 70 of IGF-1).^[5] As a result of this difference, it has considerably reduced binding to the insulin-like growth factor-binding proteins (IGFBPs) and enhanced potency (about 10-fold in vivo) relative to IGF-1.^[1]^[2]^[3]^[5]

The amino acid sequence of des(1-3)IGF-1 is TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSA.^[5]

References

^ ^a ^b Gillespie C, Read LC, Bagley CJ, Ballard FJ (1990). "Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice". J. Endocrinol. 127 (3): 401–5. doi:10.1677/joe.0.1270401. PMID 2280209.
^ ^a ^b Simes JM, Wallace JC, Walton PE (1991). "The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells". J. Endocrinol. 130 (1): 93–9. doi:10.1677/joe.0.1300093. PMID 1715381.
^ ^a ^b Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM (1996). "Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I". Int. J. Biochem. Cell Biol. 28 (10): 1085–7. doi:10.1016/1357-2725(96)00056-8. PMID 8930132.
^ Yamamoto H, Murphy LJ (1995). "Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action". J. Endocrinol. 146 (1): 141–8. doi:10.1677/joe.0.1460141. PMID 7561610.
^ ^a ^b ^c Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252–. ISBN 978-1-118-03514-6.

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Des(1-3)IGF-1
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[pmid2280209-1] Gillespie C, Read LC, Bagley CJ, Ballard FJ (1990). "Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice". J. Endocrinol. 127 (3): 401–5. doi:10.1677/joe.0.1270401. PMID 2280209.

[pmid1715381-2] Simes JM, Wallace JC, Walton PE (1991). "The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells". J. Endocrinol. 130 (1): 93–9. doi:10.1677/joe.0.1300093. PMID 1715381.

[pmid8930132-3] Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM (1996). "Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I". Int. J. Biochem. Cell Biol. 28 (10): 1085–7. doi:10.1016/1357-2725(96)00056-8. PMID 8930132.

[pmid7561610-4] Yamamoto H, Murphy LJ (1995). "Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action". J. Endocrinol. 146 (1): 141–8. doi:10.1677/joe.0.1460141. PMID 7561610.

[Thevis2010-5] Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252–. ISBN 978-1-118-03514-6.

[1]

[2]

[3]

[4]

[5]

Clinical data
Routes of administration	Intravenous administration
ATC code	None
Identifiers
CAS Number	112603-35-7^Y
ChemSpider	none
UNII	AG0WVP88OA
Chemical and physical data
Formula	C₃₁₉H₅₀₁N₉₁O₉₆S₇
Molar mass	7371.48 g·mol⁻¹

See also

References